| Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. |
globenewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier |
Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals. |
seekingalpha.com |
2025-03-25 02:58:13 |
Czytaj oryginał (ang.) |
| Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy |
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors. |
globenewswire.com |
2025-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics: In Decline, But Why? |
Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash position, supporting ongoing research and development efforts without immediate capital concerns. Strengths include a robust pipeline and innovative approach, while risks involve clinical trial uncertainties and market competition. |
seekingalpha.com |
2025-03-13 17:47:33 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. |
globenewswire.com |
2025-03-06 18:01:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts |
Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX's $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535. |
seekingalpha.com |
2024-12-30 17:07:22 |
Czytaj oryginał (ang.) |
| Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know |
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-12-11 15:01:10 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-11-05 10:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: |
globenewswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data |
Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic. |
seekingalpha.com |
2024-10-08 19:24:02 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway |
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026. |
globenewswire.com |
2024-10-07 20:01:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations |
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed |
globenewswire.com |
2024-09-23 11:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC |
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass. |
globenewswire.com |
2024-09-22 14:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 |
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health |
globenewswire.com |
2024-09-14 07:30:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy |
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-08-08 17:01:18 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-08-06 11:30:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment |
globenewswire.com |
2024-06-01 14:00:00 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference |
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY. |
globenewswire.com |
2024-05-29 12:00:00 |
Czytaj oryginał (ang.) |
| Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? |
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
zacks.com |
2024-05-10 13:51:38 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update |
CAMBRIDGE, MA, May 09, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. |
globenewswire.com |
2024-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable |
Black Diamond (BDTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-04-29 13:51:13 |
Czytaj oryginał (ang.) |
| Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-04-25 14:56:05 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL. The two poster presentations describe data for BDTX-1535 in patients with recurrent glioblastoma (GBM) across two clinical trials: a Phase 1 dose escalation trial, for which topline data were released in December 2023, and a Phase 0/1 “trigger” (“window of opportunity”) trial conducted as an Investigator Sponsored Trial at the Ivy Brain Tumor Center (NCT06072586). |
globenewswire.com |
2024-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? |
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-04-15 17:01:16 |
Czytaj oryginał (ang.) |
| Black Diamond Therapeutics Announces Changes to Board of Directors |
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. |
globenewswire.com |
2024-04-11 12:00:00 |
Czytaj oryginał (ang.) |